Randomized phase II study of zoledronate administration schedule comparing every 4 weeks versus every 8 weeks for metastatic lung cancer with bone metastasis
Phase 2
Recruiting
- Conditions
- Primary lung cancer
- Registration Number
- JPRN-UMIN000009369
- Lead Sponsor
- Institute of Biomedical Research and Innovation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with a history of intravenous bisphosphonate therapy 2)Uncontrolled co-morbidities and/or infectious diseases 3)Women who are pregnant, have a desire to bear children or in lactation 4)Recent (within 4 weeks) tooth extraction due to dental infection 5)Planned dental or jaw surgery (e.g., extraction, implants) 6)Any other current malignancy or malignancy diagnosed within the past five years. 7)Patients deemed unacceptable for inclusion to the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method